# DNA Script

> DNA Script is a French life-sciences technology company that pioneered Enzymatic DNA Synthesis (EDS) and built the SYNTAX System, the first benchtop DNA printer that lets researchers make custom DNA oligonucleotides on-site in hours instead of waiting days for outsourced orders. Founded in 2014 in Le Kremlin-Bicetre near Paris, the company aims to make biology programmable by putting rapid, template-free DNA production directly on the lab bench.

- **Founded:** 2014
- **Headquarters:** Le Kremlin-Bicetre, Ile-de-France, France
- **Founders:** Thomas Ybert (Co-founder, former CEO, now Chief Scientific Officer), Sylvain Gariel (Co-founder), Xavier Godron (Co-founder)
- **Team size:** ~140 employees
- **Products:** SYNTAX System, SYNTAX 96 Hi-Fidelity Kits, SYNTAX 96 Standard Kits, Enzymatic DNA Synthesis (EDS) technology
- **Notable:** Commercially launched the SYNTAX System in 2021 - the first benchtop DNA printer powered by enzymatic synthesis., Raised roughly $315M in total funding, including a $200M Series C, to commercialize the platform., Reinvented a 40-year-old DNA synthesis process by replacing hazardous phosphoramidite chemistry with a template-free enzymatic method.

## Products & services

- **SYNTAX System** — The first benchtop DNA printer powered by Enzymatic DNA Synthesis (EDS). A fully integrated, automated instrument that synthesizes up to 96 DNA oligos in parallel and delivers them ready-to-use, with under 15 minutes of hands-on setup and synthesis in as little as six hours.
- **SYNTAX 96 Hi-Fidelity Kits** — Reagents and consumables for parallel enzymatic synthesis of 96 ready-to-use DNA oligos up to 120 nucleotides in length, for high-accuracy applications such as gene assembly, protein mutagenesis, and CRISPR gene editing.
- **SYNTAX 96 Standard Kits** — Reagents and consumables for synthesis of 96 ready-to-use DNA oligos up to 80 nucleotides in length for everyday molecular biology workflows.
- **Enzymatic DNA Synthesis (EDS) technology** — A proprietary template-free method that uses an engineered enzyme and a 3' reverse terminator to switch nucleotide incorporation on and off, building DNA the way nature does rather than through hazardous phosphoramidite chemistry.

## Achievements

- Commercially launched the SYNTAX System in 2021 - the first benchtop DNA printer powered by enzymatic synthesis.
- Raised roughly $315M in total funding, including a $200M Series C, to commercialize the platform.
- Reinvented a 40-year-old DNA synthesis process by replacing hazardous phosphoramidite chemistry with a template-free enzymatic method.
- Enabled on-site synthesis of 96 oligos in parallel with under 15 minutes of hands-on time and results in about six hours.
- Selected by CEPI to help accelerate pandemic-response vaccine manufacturing through automated synthetic DNA templates.

## Latest updates

- **2024-10** — Marc Montserrat appointed CEO to drive long-term commercial growth; founding CEO Thomas Ybert transitioned to Chief Scientific Officer.
- **2025-01** — Signed an MoU with EVA Pharma and Quantoom Biosciences to build Africa's first end-to-end mRNA production platform.
- **2025-01** — CEPI committed ~US$4.7M to advance automation of synthetic DNA template manufacturing for faster vaccine response.
- **2026-03** — Expanded global reach with SYNTAX distribution agreements across Gencell, BMS, and Biostream in Asia-Pacific.

## Links

- Website: https://www.dnascript.com
- LinkedIn: https://www.linkedin.com/company/dna-script
- Twitter/X: https://twitter.com/dnascript
- YouTube: https://www.youtube.com/c/DNAScript

---

Profile page: https://yespress.io/dna-script
Published by YesPress — https://yespress.io
Last updated: 2026-07-15